Especially now, in the era of innovative therapies, analyses are available indicating that intensive lipid-lowering therapy, especially combination therapy with the use of PCSK9 inhibitors, may translate into a highly significant reduction in the risk of patients with multibed disease, and the more advanced the disease (more beds involved), the greater the benefits
Most GLP-1 side effects are temporary and diminish as your body adapts
Weight Loss Results 12 mg retatrutide group: Average weight loss: 28.7% , or 32 kg / 71 lbs 9 mg group: Weight loss: 26.4% Placebo group : Weight loss: 2.1% [9] Pain Reduction (WOMAC Score) Pain levels from knee osteoarthritis also improved significantly
Other options While semaglutide and tirzepatide are generally the most talked about, theyre not the only GLP-1s on the market
Pocai A, et al
Retreatment of patients who had virologic failure to G/P therapy may require a regimen with more than two mechanisms of action, such as G/P plus SOF, which is a DAA combination currently being evaluated in an ongoing clinical study (registered clinical trial: NCT02939989)
